B
buffalo
Guest
Critic points out media bias against adult stem cells
Seattle, Wash., Nov 25, 2011 / 08:52 am (CNA).- After researchers in California called off a major U.S. embryonic stem cell study, a legal expert says that most major news outlets have given zero coverage to the far superior benefits of adult stem cells.
“Since embryonic stem cells were first derived, the media has told a materially unbalanced story,” said Wesley J. Smith, a lawyer and senior fellow at the Discovery Institute’s Center on Human Exceptionalism.
Smith said in a Nov. 23 interview with CNA that successful adult stem cell clinical trials “have either been ignored totally, or generally underplayed as story after story has claimed adult approaches offer more limited benefits than embryonic.”
His remarks come as the California-based biopharmecuetical company Geron announced on Nov. 18 that it has dropped a widely publicized embryonic stem cell research study.
Geron said that the FDA-approved study, which began in 2009 in attempt to treat spinal chord injuries, would have to end due to “capital scarcity.”
Fr. Tomasz Trafny, a member of the Vatican’s Council for Culture, said the move shows how companies are beginning to see that it’s “not worth it to invest money, energy,” and “human potentiality” in embryonic stem cell research.
more…
Seattle, Wash., Nov 25, 2011 / 08:52 am (CNA).- After researchers in California called off a major U.S. embryonic stem cell study, a legal expert says that most major news outlets have given zero coverage to the far superior benefits of adult stem cells.
“Since embryonic stem cells were first derived, the media has told a materially unbalanced story,” said Wesley J. Smith, a lawyer and senior fellow at the Discovery Institute’s Center on Human Exceptionalism.
Smith said in a Nov. 23 interview with CNA that successful adult stem cell clinical trials “have either been ignored totally, or generally underplayed as story after story has claimed adult approaches offer more limited benefits than embryonic.”
His remarks come as the California-based biopharmecuetical company Geron announced on Nov. 18 that it has dropped a widely publicized embryonic stem cell research study.
Geron said that the FDA-approved study, which began in 2009 in attempt to treat spinal chord injuries, would have to end due to “capital scarcity.”
Fr. Tomasz Trafny, a member of the Vatican’s Council for Culture, said the move shows how companies are beginning to see that it’s “not worth it to invest money, energy,” and “human potentiality” in embryonic stem cell research.
more…